Oppenheimer Upgrades BioMarin: Long-Term Outlook Brightens

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has received a significant boost in its long-term outlook, as Oppenheimer upgrades the biotech company's stock rating. This upgrade reflects BioMarin's strong financial performance, operational transformation, and promising pipeline, which are likely to contribute to the company's long-term growth and success.

BioMarin's operational transformation and strong financial execution in 2024 have set the stage for double-digit revenue and profitability growth in 2025. The company's Skeletal Conditions business unit, led by the continued global expansion of VOXZOGO for achondroplasia, is expected to drive strong execution and growth. Additionally, BioMarin plans to execute on its business development strategy and advance five new VOXZOGO indications within its CANOPY clinical program.

The company's pipeline of innovative therapies, such as BMN 351 for Duchenne Muscular Dystrophy and BMN 333 for multiple skeletal conditions, also contributes to BioMarin's long-term growth potential. These therapies target unmet medical needs and expand the company's portfolio of treatments for rare diseases. Key milestones to watch for in these programs include early clinical data read-outs, regulatory submissions, and the advancement of new indications.

The recent publication of international treatment guidelines recommending early screening and VOXZOGO treatment for achondroplasia could further enhance BioMarin's market share and revenue growth in the Skeletal Conditions business unit. These guidelines provide healthcare professionals and families with confidence in VOXZOGO as the treatment of choice, potentially leading to more prescriptions and earlier treatment for children with achondroplasia.



BioMarin's strong financial performance, operational transformation, and promising pipeline have led Oppenheimer to upgrade the company's long-term outlook. As Alexander Hardy, President and Chief Executive Officer of BioMarin, stated, "We expect 2025 to be another year of strong execution and growth in our Skeletal Conditions business unit, led by the continued global expansion of VOXZOGO for achondroplasia." The recent publication of international treatment guidelines recommending early screening and VOXZOGO treatment for achondroplasia could contribute to this expected growth.



In conclusion, Oppenheimer's upgrade of BioMarin's long-term outlook reflects the company's strong financial performance, operational transformation, and promising pipeline. As BioMarin continues to execute on its growth strategy and advance its innovative therapies, investors can expect the company to maintain its momentum and deliver long-term growth.